Information filters

  • TIES®
  • Corporate
  • Job postings
  • Articles
  • Patients
  • General

Technical File submitted for CE approval of TIES®

Comprising an implantable medical device, the TIES® System requires approval from a Notified Body in order to obtain CE marking and to be marketed in Europe. A complete Technical File for the TIES® System has now been submitted to the Notified Body for OstomyCure for thorough evaluation and subsequent approval.

Latest update on the TIES® Solution – May 2020

2020-05-28

Message from Ostomycure CEO, Graeme Smith.

New Stockholm office

2020-05-14

OstomyCure has moved its Stockholm operations from Kista to the Karolinska Campus area in Solna in the heart of the bustling Stockholm life science scene.

First Patients enrolled in the C03 clinical study in the UK

2019-06-09

Today the first patient was enrolled in the TIES03 study of the OstomyCure Transcuteous Implant Evacuation System (TIES®).

OstomyCure® AS receives the most sought-after Horizon 2020 EU grant of € 2.5 Mio.

2019-02-20

OstomyCure AS® has received a EU grant of € 2.5 Mio. via the Horizon 2020 Project.

Large clinical study started in UK and Sweden

2018-06-05

Approval for multicenter study “TIES-C03” in major university hospitals in Leeds, UK & Umeå, Sweden.

Latest update on TIES Solution

2018-01-11

Message from CEO Ostomycure Dr Benedict Broenniman M.D.

OstomyCure AS Appoints new Chief Medical Officer

2017-01-31

OstomyCure today announced the appointment of Cindy Wong, M.D. as Chief Medical Officer (CMO).

Article in IA Journal: Issue 233 Autumn 2016

2016-11-10

OstomyCure AS has been published in The Ileostomy & Internal Pouch Support Groups latest issue of the IA Journal.

Experienced Chief Commercial Officer Joins OstomyCure AS

2016-09-26

OstomyCure AS engages Morten Gunvad, currently founder and Head of GP Consulting GmbH, as Chief Commercial Officer of the TIES® System.